Targeted biocompatible nanoparticles for the delivery of (-)-epigallocatechin 3-gallate to prostate cancer cells

Journal of Medicinal Chemistry

Volumn 54, Issue 5, 2011, Pages 1321-1332

  Sanna, Vanna ^a   Pintus, Gianfranco ^b   Roggio, Anna Maria ^a   Punzoni, Stefania ^b   Posadino, Anna Maria ^a,b   Arca, Alessandro ^b   Marceddu, Salvatore ^c   Bandiera, Pasquale ^b   Uzzau, Sergio ^a,b   Sechi, Mario ^b  

^a Porto Conte Ricerche Srl   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

^c INSTITUTE OF SCIENCES OF FOOD PRODUCTION   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIGALLOCATECHIN GALLATE; NANOPARTICLE; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCOMPATIBILITY; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SELECTIVITY; DRUG SOLUBILITY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; NANOENCAPSULATION; PROSTATE CANCER; PROTEIN EXPRESSION;

ANTICARCINOGENIC AGENTS; CATALYTIC DOMAIN; CATECHIN; CELL LINE, TUMOR; CELL PROLIFERATION; DIPEPTIDES; DRUG CARRIERS; HUMANS; KINETICS; MALE; MOLECULAR TARGETED THERAPY; NANOPARTICLES; POLYESTERS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 79952265869     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1013715     Document Type: Article

References (51)

1. Farokhzad, O. C.; Langer, R. Impact of nanotechnology on drug delivery ACS Nano 2009, 3, 16-20
2. Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy Nat. Nanotechnol. 2007, 2, 751-760 (Pubitemid 350223348)
3. Ferrari, M. Cancer nanotechnology: opportunities and challenges Nat. Rev. Cancer 2005, 5, 161-171 (Pubitemid 40314948)
4. Davis, M. E.; Chen, Z. G.; Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer Nat. Rev. Cancer 2008, 7, 771-782
5. Zhang, L.; Gu, F. X.; Chan, J. M.; Wang, A. Z.; Langer, R. S.; Farokhzad, O. C. Nanoparticles in medicine: therapeutic applications and developments Clin. Pharmacol. Ther. 2008, 83, 761-769 (Pubitemid 351556021)
6. Shi, J.; Votruba, A. R.; Farokhzad, O. C.; Langer, R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications Nano Lett. 2010, 10, 3223-3230
7. Gu, F.; Langer, R.; Farokhzad, O. C. Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery Methods Mol. Biol. 2009, 544, 589-598
8. Byrne, J. D.; Betancourt, T.; Brannon-Peppas, L. Active targeting schemes for nanoparticle systems in cancer therapeutics Adv. Drug Delivery Rev. 2008, 60, 1615-1626
9. Alexis, F.; Pridgen, E.; Molnar, L. K.; Farokhzad, O. C. Factors affecting the clearance and biodistribution of polymeric nanoparticles Mol. Pharmaceutics 2008, 5, 505-515
10. Alexis, F.; Pridgen, E. M.; Langer, R.; Farokhzad, O. C. Nanoparticle technologies for cancer therapy Handb. Exp. Pharmacol. 2010, 197, 55-86
11. Siu, D. Cancer therapy using tumor-associated antigens to reduce side effects Clin. Exp. Med. 2009, 9, 181-198
12. Cozzi, P. J.; Kearsley, J.; Li, Y. Overview of tumor-associated antigens (TAAs) as potential therapeutic targets for prostate cancer therapy Curr. Cancer Ther. Rev. 2008, 4, 271-284
13. Chang, S. S.; O'Keefe, D. S.; Bacich, D. J.; Reuter, V. E.; Heston, W. D.; Gaudin, P. B. Prostate-specific membrane antigen is produced in tumor-associated neovasculature Clin. Cancer Res. 1999, 5, 2674-2681 (Pubitemid 29493938)
14. Ghosh, A.; Heston, W. D. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer J. Cell. Biochem. 2004, 91, 528-539
15. Schülke, N.; Varlamova, O. A.; Donovan, G. P.; Ma, D.; Gardner, J. P.; Morrissey, D. M.; Arrigale, R. R.; Zhan, C.; Chodera, A. J.; Surowitz, K. G. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 12590-12595 (Pubitemid 37339943)
16. Elsässer-Beile, U.; Bühler, P.; Wolf, P. Targeted therapies for prostate cancer against the prostate specific membrane antigen Curr. Drug Targets 2009, 10, 118-125
17. Farokhzad, O. C.; Cheng, J.; Teply, B. A.; Sherifi, I.; Jon, S.; Kantoff, P. W.; Richie, J. P.; Langer, R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 6315-6320
18. Gu, F.; Zhang, L.; Teply, B. A.; Mann, N.; Wang, A.; Radovic-Moreno, A. F.; Langer, R.; Farokhzad, O. C. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 2586-2591 (Pubitemid 351520557)
19. Surh, Y.-J. Cancer chemoprevention with dietary phytochemicals Nat. Rev. Cancer 2003, 3, 768-780 (Pubitemid 37328815)
20. Siddiqui, I. A.; Mukhtar, H. Nanochemoprevention by bioactive food components: a perspective Pharm. Res. 2010, 27, 1054-1060
21. Siddiqui, I. A.; Adhami, V. M.; Ahmad, N.; Mukhtar, H. Nanochemoprevention: sustained release of bioactive food components for cancer prevention Nutr. Cancer 2010, 62, 883-890
22. Saleem, M.; Adhami, V. M.; Siddiqui, I. A.; Mukhtar, H. Tea beverage in chemoprevention of prostate cancer: a mini-review Nutr. Cancer 2003, 47, 13-23 (Pubitemid 38250431)
23. Yang, C. S.; Wang, X.; Lu, G.; Picinich, S. C. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance Nat. Rev. Cancer 2009, 9, 429-439
24. Johnson, J. J.; Bailey, H. H.; Mukhtar, H. Green tea polyphenols for prostate cancer chemoprevention: a translational perspective Phytomedicine 2010, 17, 3-13
25. Khan, N.; Adhami, V. M.; Mukhtar, H. Review: green tea polyphenols in chemoprevention of prostate cancer: preclinical and clinical studies Nutr. Cancer 2009, 61, 836-841
26. Kurahashi, N.; Sasazuki, S.; Iwasaki, M.; Inoue, M.; Tsugane, S. Green tea consumption and prostate cancer risk in Japanese Men: a prospective study Am. J. Epidemiol. 2008, 167, 71-77
27. Siddiqui, I. A.; Adhami, V. M.; Bharali, D. J.; Hafeez, B. B.; Asim, M.; Khwaja, S. I.; Ahmad, N.; Cui, H.; Mousa, S. A.; Mukhtar, H. Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate Cancer Res. 2009, 69, 1712-1716
28. Bettuzzi, S.; Brausi, M.; Rizzi, F.; Castagnetti, G.; Peracchia, G.; Corti, A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study Cancer Res. 2006, 66, 1234-1240 (Pubitemid 43165995)
29. Brausi, M.; Rizzi, F.; Bettuzzi, S. Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update Eur. Urol. 2008, 54, 472-473
30. Leonarduzzi, G.; Testa, G.; Sottero, B.; Gamba, P.; Poli, G. Design and development of nanovehicle-based delivery systems for preventive or therapeutic supplementation with flavonoids Curr. Med. Chem. 2010, 17, 74-95
31. Otsuka, H.; Nagasaki, Y.; Kataoka, K. PEGylated nanoparticles for biological and pharmaceutical applications Adv. Drug Delivery Rev. 2003, 55, 403-419 (Pubitemid 36293792)
32. Avgoustakis, K. Pegylated poly(lactide) and poly(lactide-coglycolide) nanoparticles: preparation, properties and possible applications in drug delivery Curr. Drug Delivery 2004, 1, 321-333
33. Betancourt, T.; Byrne, J. D.; Sunaryo, N.; Crowder, S. W.; Kadapakkam, M.; Patel, S.; Casciato, S.; Brannon-Peppas, L. PEGylation strategies for active targeting of PLA/PLGA nanoparticles J. Biomed. Mater. Res., Part A 2009, 91, 263-276
34. Chandran, S. S.; Banerjee, S. R.; Mease, R. C.; Pomper, M. G.; Denmeade, S. R. Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA) Cancer Biol. Ther. 2008, 7, 974-982
35. Maresca, K. P.; Hillier, S. M.; Femia, F. J.; Keith, D.; Barone, C.; Joyal, J. L.; Zimmerman, C. N.; Kozikowski, A. P.; Barrett, J. A.; Eckelman, W. C. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer J. Med. Chem. 2009, 52, 347-357
36. Byun, Y.; Mease, R. C.; Lupold, S. E.; Pomper, M. G. In Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications; Supuran, C. T.; Winum, J.-Y., Eds.; Binghe Wang Wiley Series in Drug Discovery and Development; John Wiley and Sons: Hoboken, NJ, 2009; pp 881 - 910.
37. Zhou, J.; Neale, J. H.; Pomper, M. G.; Kozikowski, A. P. NAAG peptidase inhibitors and their potential for diagnosis and therapy Nat. Rev. Drug Discovery 2005, 4, 1015-1026
38. Davis, M. I.; Bennett, M. J.; Thomas, L. M.; Bjorkman, P. J. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 5981-5986 (Pubitemid 40594241)
39. Mesters, J. R.; Barinka, C.; Li, W.; Tsukamoto, T.; Majer, P.; Slusher, B. S.; Konvalinka, J.; Hilgenfeld, R. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer EMBO J. 2006, 25, 1375-1384
40. Barinka, C.; Byun, Y.; Dusich, C. L.; Banerjee, S. R.; Chen, Y.; Castanares, M.; Kozikowski, A. P.; Mease, R. C.; Pomper, M. G.; Lubkowski, J. Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization J. Med. Chem. 2008, 51, 7737-7743
41. Barinka, C.; Rovenská, M.; MLcochová, P.; Hlouchová, K.; Plechanovová, A.; Majer, P.; Tsukamoto, T.; Slusher, B. S.; Konvalinka, J.; Lubkowski, J. Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II J. Med. Chem. 2007, 50, 3267-3273 (Pubitemid 47065975)
42. Gref, R.; Minamitake, Y.; Peracchia, M. T.; Trubetskoy, V.; Torchilin, V.; Langer, R. Biodegradable long-circulating polymeric nanospheres Science 1994, 263, 1600-1603 (Pubitemid 24128361)
43. Gref, R.; Luck, M.; Quellec, P.; Marchand, M.; Dellacherie, E.; Harnisch, S.; Blunk, T.; Muller, R. H. "Stealth" corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption Colloids Surf., B 2000, 18, 301-313 (Pubitemid 30479870)
44. Cheng, J.; Teply, B. A.; Sherifi, I.; Sung, J.; Luther, G.; Gu, F. X.; Levy-Nissenbaum, E.; Radovic-Moreno, A. F.; Langer, R.; Farokhzad, O. C. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery Biomaterials 2007, 28, 869-876 (Pubitemid 44667020)
45. Banerjee, S. R.; Foss, A. C.; Castanares, M.; Mease, R. C.; Byun, Y.; Fox, J. J.; Hilton, J.; Lupold, S. E.; Kozikowski, A. P.; Pomper, M. G. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA) J. Med. Chem. 2008, 51, 4504-4517
46. Maclaren, J. A. Some amino acid esters - an improved preparative method Aust. J. Chem. 1978, 31, 1865-1868
47. Lee, E. S.; Oh, K. T.; Kim, D.; Youn, Y. S.; Bae, Y. H. Tumor pH-responsive flower-like micelles of poly(l -lactic acid)- b- poly(ethylene glycol)- b -poly(l -histidine) J. Controlled Release 2007, 123, 19-26
48. Shutava, T. G.; Balkundi, S. S.; Vangala, P.; Steffan, J. J.; Bigelow, R. L.; Cardelli, J. A.; O'Neal, D. P.; Lvov, Y. M. Layer-by-layer-coated gelatin nanoparticles as a vehicle for delivery of natural polyphenols ACS Nano 2009, 3, 1877-1885
49. Hu, B.; Pan, C.; Sun, Y.; Hou, Z.; Ye, Y.; Hu, B.; Zeng, X. Optimization of fabrication parameters to produce chitosan-tripolyphosphate nanoparticles for delivery of tea catechins J. Agric. Food Chem. 2008, 56, 7451-7458
50. 18F]DCFBC: a new imaging probe for prostate cancer Clin. Cancer Res. 2008, 14, 3036-3043
51. Saito, S. T.; Welzel, A.; Suyenaga, E. S.; Bueno, F. A method for fast determination of epigallocatechin gallate (EGCG), epicatechin (EC), catechin (C) and caffeine (CAF) in green tea using HPLC Cienc. Tecnol. Aliment. 2006, 26, 394-400 (Pubitemid 44178895)